Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
EcgonineN I JUN / 02
Econazole or its saltsPDL I DEC / 13
Ecothiophate or its saltsPDL I DEC / 13
Ectylurea or its saltsPDL I DEC / 13
EculizumabPDL I DEC / 13
Edoxaban or its saltsPDL I FEB / 17
Edrophonium chloridePDL I DEC / 13
EfalizumabPDL I DEC / 13
EfavirenzPDL I DEC / 13
EfinaconazolePDL I DEC / 13
Eflornithine or its salts or derivativesPDL I DEC / 13
Elbasvir or its saltsPDL I AUG / 16
Electrolyte solutions for oral rehydration III SEP / 98
Eletriptan or its saltsPDL I DEC / 13
Eliglustat or its saltsPDL I MAY / 17
Elosulfase alfaPDL I AUG / 14
ElotuzumabPDL I AUG / 16
Eltrombopag or its saltsPDL

including but not limited to eltrombopag olamine

I DEC / 13
Eluxadoline or its saltsPDL I APR / 17
Emamectin or its saltsPDL

including but not limited to emamectin benzoate

I DEC / 13
EmbutramidePDL I DEC / 13
Emedastine or its saltsPDL I DEC / 13
EmpagliflozinPDL I OCT / 15
EmtricitabinePDL I DEC / 13
EmylcamatePDL I DEC / 13
Enalapril or its salts or derivativesPDL

including but not limited to enalapril maleate

I DEC / 13
Encephalitis vaccine (Japanese) I FEB / 02
EnestebolC3 I JUN / 02
EnfluranePDL I DEC / 13
EnfuvirtidePDL I DEC / 13
Enoxaparin or its saltsPDL I DEC / 13
EnrofloxacinPDL I DEC / 13
EntacaponePDL I DEC / 13
EntecavirPDL I DEC / 13
EnzalutamidePDL I DEC / 13
Ephedrine and its salts

in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion.

I FEB / 02
Ephedrine and its salts in combination products in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. III APR / 06
Ephedrine and its salts in single entity products. in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. II APR / 06
Epinephrine and its salts in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens II SEP / 99
Epinephrine and its salts. other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens I SEP / 99
Epirubicine or its saltsPDL I DEC / 13
EpitiostanolC3 I JUN / 02
EplerenonePDL I DEC / 13
Eprosartan or its salts or derivativesPDL I DEC / 13
EpsiprantelPDL I DEC / 13
Eptifibatide or its saltsPDL I DEC / 13
Ergot alkaloids or their saltsPDL

for human use

I DEC / 13
Eribulin or its salts or derivativesPDL

including but not limited to eribulin mesylate

I DEC / 13
Erlotinib or its saltsPDL I DEC / 13
Ertapenem or its saltsPDL I DEC / 13
Ertugliflozin or its derivativesPDL I JUL / 18
Erythrityl tetranitrate I SEP / 98
Erythromycin or its salts or derivativesPDL

including but not limited to tulathromycin

I DEC / 13
Erythropoiesis stimulating hormonePDL

including but not limited to erythropoietin, darbepoetin alpha, epoetin alfa

I DEC / 13
Escitalopram or its saltsPDL I DEC / 13
Esdepallethrin/piperonyl butoxide II SEP / 98
Eslicarbazepine acetatePDL I AUG / 14
Esmolol or its saltsPDL I DEC / 13
Esomeprazole or its saltsPDL

including but not limited to esomeprazole magnesium except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole

I AUG / 16
Esomeprazole or its salts. when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole II AUG / 16
Esomeprazole or its salts..PDL

for veterinary use

I DEC / 13
Estazolam and its saltsTS I SEP / 98
Estramustine or its saltsPDL I DEC / 13
EtanerceptPDL I DEC / 13
Ethacrynic acidPDL I DEC / 13
Ethambutol or its saltsPDL I DEC / 13
Ethanolamine oleate II SEP / 98
EthchlorvynolTS I SEP / 98
EthinamateTS I SEP / 98
Ethionamide or its saltsPDL I DEC / 13
Ethoheptazine and its salts II SEP / 98
Ethomoxane or its saltsPDL I DEC / 13
Ethotoin or its saltsPDL I DEC / 13
Ethyl Chloride except in trace amounts II SEP / 98
Ethyl LoflazepateTS I JUN / 02
Ethyl trichloramatePDL I DEC / 13
EthylestrenolC3 I JUN / 02
EthylmethylthiambuteneN I JUN / 02
EthylmorphineN I JUN / 02
Ethylpapaverine and its salts I SEP / 98
Etidronic acid or its saltsPDL I DEC / 13
Etodolac or its salts or derivativesPDL I DEC / 13
EtonitazeneN I JUN / 02
Etoposide or its derivativesPDL I DEC / 13
EtorphineN I JUN / 02
EtoxeridineN I JUN / 02
Etravirine or its saltsPDL I DEC / 13
EtretinatePDL I DEC / 13
Etryptamine and its salts I SEP / 98
Etymemazine or its saltsPDL I DEC / 13
EvolocumabPDL I JAN / 16
ExemestanePDL I DEC / 13
Exenatide or its saltsPDL I DEC / 13
EzetimibePDL I DEC / 13
Ezogabine or its salts or derivativesPDL I DEC / 13

95 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled